In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on CytomX Therapeutics (CTMX), with a price target of $16.00. The company’s shares closed last Monday at $6.70.
According to TipRanks.com, Goldstein has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.7% and a 32.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Fate Therapeutics, and Arcus Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CytomX Therapeutics with a $14.25 average price target, which is a 122.0% upside from current levels. In a report issued on March 24, Wedbush also upgraded the stock to Buy with a $10.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.64 and a one-year low of $3.60. Currently, CytomX Therapeutics has an average volume of 433.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
